These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31057792)

  • 41. Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients.
    Peña C; Gómez-Zorrilla S; Suarez C; Dominguez MA; Tubau F; Arch O; Oliver A; Pujol M; Ariza J
    Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2791-7. PubMed ID: 22552893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the systemic inflammatory response syndrome between monomicrobial and polymicrobial Pseudomonas aeruginosa nosocomial bloodstream infections.
    Marra AR; Bearman GM; Wenzel RP; Edmond MB
    BMC Infect Dis; 2005 Oct; 5():94. PubMed ID: 16259623
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.
    Endimiani A; Luzzaro F; Pini B; Amicosante G; Rossolini GM; Toniolo AQ
    BMC Infect Dis; 2006 Mar; 6():52. PubMed ID: 16542460
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan.
    Tseng SP; Tsai JC; Teng LJ; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1170-4. PubMed ID: 19773253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.
    Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N
    Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hospital mortality and length of stay associated with
    Cooper L; Yu K; Van Benten K; Patkar A; Ye G; Gregory S; Ai C; Gupta V
    Microbiol Spectr; 2024 Aug; 12(8):e0040224. PubMed ID: 38953323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carbapenem-resistant-only Pseudomonas aeruginosa infection in patients formerly infected by carbapenem-susceptible strains.
    Tsai MH; Wu TL; Su LH; Lo WL; Chen CL; Liang YH; Chiu CH
    Int J Antimicrob Agents; 2014 Dec; 44(6):541-5. PubMed ID: 25264129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in
    Kang JS; Moon C; Mun SJ; Lee JE; Lee SO; Lee S; Lee SH
    J Korean Med Sci; 2021 Nov; 36(43):e273. PubMed ID: 34751008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors for hospitalized patients with resistant or multidrug-resistant
    Raman G; Avendano EE; Chan J; Merchant S; Puzniak L
    Antimicrob Resist Infect Control; 2018; 7():79. PubMed ID: 29997889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections.
    Lin KY; Lauderdale TL; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2016 Feb; 49(1):52-9. PubMed ID: 24662016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram-negative Bloodstream Infections: "Every day matters".
    Lodise TP; Kanakamedala H; Hsu WC; Cai B
    Pharmacotherapy; 2020 Sep; 40(9):889-901. PubMed ID: 33112456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
    Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of metallo-β-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosa bloodstream infection: a retrospective cohort study.
    Willmann M; Kuebart I; Marschal M; Schröppel K; Vogel W; Flesch I; Markert U; Autenrieth IB; Hölzl F; Peter S
    BMC Infect Dis; 2013 Nov; 13():515. PubMed ID: 24176052
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Herrera S; Morata L; Sempere A; Verdejo M; Del Rio A; Martínez JA; Cuervo G; Hernández-Meneses M; Chumbita M; Pitart C; Puerta P; Monzó P; Lopera C; Aiello F; Mendoza S; Garcia-Vidal C; Soriano A; Bodro M
    Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.
    Hattemer A; Hauser A; Diaz M; Scheetz M; Shah N; Allen JP; Porhomayon J; El-Solh AA
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3969-75. PubMed ID: 23733476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Shifting trends and age distribution of ESKAPEEc resistance in bloodstream infection, Southwest China, 2012-2017.
    Yang S; Xu H; Sun J; Sun S
    Antimicrob Resist Infect Control; 2019; 8():61. PubMed ID: 30976388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular epidemiological survey of the quinolone- and carbapenem-resistant genotype and its association with the type III secretion system in Pseudomonas aeruginosa.
    Ferreira ML; Dantas RC; Faria ALS; Gonçalves IR; Silveira de Brito C; Queiroz LL; Gontijo-Filho PP; Ribas RM
    J Med Microbiol; 2015 Mar; 64(Pt 3):262-271. PubMed ID: 25596115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
    Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
    Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
    Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
    J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.